Amsterdam, June 6, 2021 – DEARhealth, a health tech company focused on AI-powered chronic disease management, today announced that it has obtained certification for ISO 13485 (quality management systems for medical devices) and the certificate of conformity according to the European Union Medical Device Regulation (MDR) as a class IIa medical device for the first release of the DEARhealth patient and care software.

Munich, Germany, May 4, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L'Huillier as Chief Executive Officer (CEO), effective May 17, 2021.

Boston (April 21, 2021) – Caresyntax, the leading enterprise-level digital surgery platform delivering actionable insights to make surgery smarter and safer, today announced that it has closed an oversubscribed $100 million Series C funding round led by PFM Health Sciences LP, which also included participation from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital, Rezayat Investments, as well as current investors IPF Partners, the Relyens Group, and Surgical.AI.

DEARhealth Recruits Senior Executives to Accelerate Growth

• DEAR appoints Willem Houck and Reender Beks as CEO and CFO respectively; DEAR founder Daniel Hommes will assume the role of Chief Medical and Product Officer.
• DEAR is an artificial intelligence engine, which generates real time care pathway recommendations for care providers.
• DEAR is accelerating its commercialization efforts of its subscription-based Software as a Medical Device platform to Healthcare Providers.

Turku, Finland, March 3^rd, 2021 – Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women's health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzymetargeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo's therapeutic concept.

Heusden-Zolder, Belgium, 2^nd March 2021 – Rejuvenate Biomed NV ("Rejuvenate"), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round.

Munich, Germany, March 1^st 2021 – CatalYm GmbH, Announces Key Management and Board Changes:

• Dr. Manfred Ruediger steps down as Chief Executive Officer of CatalYm
• Dr. John Haurum succeeds Dr. Holger Reithinger as Chairman of the Supervisory Board

NEW YORK, 2021 – SWORD Health, the world's fastest growing virtual musculoskeletal (MSK) care provider, has raised a $25 million financing round, bringing SWORD's cumulative fundraising to $50 million. The round was led by Todd Cozzens, Managing Partner at Transformation Capital and former healthcare investor at Sequoia Capital.

Munich, Germany, January 28^th, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment.

Gosselies, 27th November 2020 – Already celebrated by Deloitte's Technology Fast50 in 2015 and 2018, OncoDNA is thrilled to announce that it has received this year's award in the biotechnology and pharmaceutical category.